<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C79EE0CB-A287-4F81-A094-E69B1EC1724A"><gtr:id>C79EE0CB-A287-4F81-A094-E69B1EC1724A</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:surname>Mead</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6443"><gtr:id>E359C7A7-75C6-441D-A5D3-DD971B4E47AC</gtr:id><gtr:title>Clinical and biological consequences of different FLT3 mutations and/or increased FLT3 expression in patients with AML</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6443</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>171128</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prognostic Significance of FLT3 mutations in AML</gtr:description><gtr:id>D9BD892F-99E4-4946-BC79-71F41CACC8E4</gtr:id><gtr:impact>Publications: 17456725, 17957027, 18606888</gtr:impact><gtr:outcomeId>971BE302502-1</gtr:outcomeId><gtr:partnerContribution>My project involved screening a large cohort of samples from an cohort of patients treated on the UK MRC clinical trials, and correlating these data with clinical outcome. These trials are run by the Haematology Dept at Cardiff University.</gtr:partnerContribution><gtr:piContribution>Data Bank of AML genomic DNA Samples and outcome data of MRC AML trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>580000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Senior Bennett Fellowship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>B5CC4DDF-9125-49A6-993A-E63785D3714D</gtr:id><gtr:outcomeId>DE8FA7A7C370</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4AB21BFF-5628-4FBC-A592-9E3B567C5BAD</gtr:id><gtr:title>Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>608E5917B22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3573A1-00D7-4F1E-8E36-6D58212080B5</gtr:id><gtr:title>The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e13de1de350fbdfe3b1038ce825cd78a"><gtr:id>e13de1de350fbdfe3b1038ce825cd78a</gtr:id><gtr:otherNames>Gale RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>878B957EF9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2497A883-7485-413D-8389-D7E2237850AA</gtr:id><gtr:title>Guideline for the investigation and management of eosinophilia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fadf094168acfb19771f896e4fc6fab"><gtr:id>1fadf094168acfb19771f896e4fc6fab</gtr:id><gtr:otherNames>Butt NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5a93da1dcb2d93.89154569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95F1C0A8-DD0B-4255-B06E-CFC0BA68FD2C</gtr:id><gtr:title>Allogeneic stem cell transplantation for myelofibrosis in 2012.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a0342fbbf54732ab2747cdacb23e7a5"><gtr:id>8a0342fbbf54732ab2747cdacb23e7a5</gtr:id><gtr:otherNames>McLornan DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>545e5ee2200f03.31305932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FFF7B4F-F78F-475E-9069-A61B3889DA49</gtr:id><gtr:title>Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38befaa024e88a98a6ac992c4bdb576"><gtr:id>a38befaa024e88a98a6ac992c4bdb576</gtr:id><gtr:otherNames>Harrison CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>545e606d882060.27534339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F0B94DF-C629-486C-8CFA-0431113EA2D4</gtr:id><gtr:title>Practical management of patients with myelofibrosis receiving ruxolitinib.</gtr:title><gtr:parentPublicationTitle>Expert review of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf4d659e55a97c6582b5ebefa14d3fa"><gtr:id>4cf4d659e55a97c6582b5ebefa14d3fa</gtr:id><gtr:otherNames>Harrison C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1747-4094</gtr:issn><gtr:outcomeId>545e5fe391fa21.06491857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB42A4D9-6984-49A7-8CA6-79AA1EF08802</gtr:id><gtr:title>FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>F70A5B0DE28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E777AE82-9189-4E99-B5FE-2DC6FBCBE89F</gtr:id><gtr:title>Application of single-cell genomics in cancer: promise and challenges.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6951a04aa0c935290484392c1117ca4"><gtr:id>e6951a04aa0c935290484392c1117ca4</gtr:id><gtr:otherNames>Wills QF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56ab5834284d91.66364025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04FA3243-53B4-4C25-AD73-49AA22ADA676</gtr:id><gtr:title>Germline counterparts of oncogenic mutations: who gives a JAK?.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>545e5e9c057ed1.14607725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5BD9193-3C12-473A-88EC-75FECEEF99E5</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545e5e9bd1b106.23176609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>586590C1-5A46-44B1-ABD4-F2C457326A6E</gtr:id><gtr:title>The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/863c8044fc8bc8103f03fb2384b7e08c"><gtr:id>863c8044fc8bc8103f03fb2384b7e08c</gtr:id><gtr:otherNames>Luc S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>545e5ee1c84743.43991075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33F14A24-23C3-46A9-8BF4-304F26069041</gtr:id><gtr:title>Persistent malignant stem cells in del(5q) myelodysplasia in remission.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96d892dd559c3e7d3575f4ae7396778"><gtr:id>a96d892dd559c3e7d3575f4ae7396778</gtr:id><gtr:otherNames>Tehranchi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>545e5ee17c78c4.26177131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C708410F-7B59-496B-A79A-D607F4D16023</gtr:id><gtr:title>Studying epigenomics in single cells: what is feasible and what can we learn?</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6951a04aa0c935290484392c1117ca4"><gtr:id>e6951a04aa0c935290484392c1117ca4</gtr:id><gtr:otherNames>Wills QF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>56ab581c195825.74271542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6570B26-CCFE-4281-BED1-38D597348435</gtr:id><gtr:title>Equivalence of BCSH and WHO diagnostic criteria for ET.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38befaa024e88a98a6ac992c4bdb576"><gtr:id>a38befaa024e88a98a6ac992c4bdb576</gtr:id><gtr:otherNames>Harrison CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5a93d9d5b526f3.86349296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5459E32-5F1A-4187-B22A-10A4091022B8</gtr:id><gtr:title>Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4de4f25ab06ec8486a5297e7e5328d"><gtr:id>3a4de4f25ab06ec8486a5297e7e5328d</gtr:id><gtr:otherNames>Goardon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>545e5fe31bbac0.45440101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8FE045D-1F0E-487F-A63A-E3A55DF4F2C3</gtr:id><gtr:title>Equivalence of BCSH and WHO diagnostic criteria for ET.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38befaa024e88a98a6ac992c4bdb576"><gtr:id>a38befaa024e88a98a6ac992c4bdb576</gtr:id><gtr:otherNames>Harrison CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5a93da5290c750.38170200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>218E5AE4-E6DF-4FE7-A3CE-76F54EB88700</gtr:id><gtr:title>Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dcbcbb174ef85060f893c5185d2dbd0"><gtr:id>9dcbcbb174ef85060f893c5185d2dbd0</gtr:id><gtr:otherNames>Sanjuan-Pla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>545e5fe3694c07.88357014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B5EC794-8B13-46F0-82B8-F7F954DA67F1</gtr:id><gtr:title>Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5020f1fc79f56da95e57541d9bb5da4"><gtr:id>d5020f1fc79f56da95e57541d9bb5da4</gtr:id><gtr:otherNames>B?iers C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>545e5e9c2c0517.15871211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1A0541C-4E04-4C80-AA62-3A6E2922C386</gtr:id><gtr:title>A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e241df9506cc57c225f4d67f9f5101c"><gtr:id>5e241df9506cc57c225f4d67f9f5101c</gtr:id><gtr:otherNames>Buono M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>56ab58985f30e1.16961361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DB36057-3745-4458-BBBA-905227ED7C38</gtr:id><gtr:title>Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56ab57eb107dc2.64994943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A54054F0-90D6-4EA9-9337-E6BFC01A6DE0</gtr:id><gtr:title>Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d776866a5dee0d8e2f2f02303fedd07"><gtr:id>0d776866a5dee0d8e2f2f02303fedd07</gtr:id><gtr:otherNames>Eyre T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545e606d6378a2.36635406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>783CE895-3756-4840-B26B-881443E5E0DD</gtr:id><gtr:title>Myeloproliferative neoplasm stem cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a93d9f3d14994.68618525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3285C20-74DC-4E44-A5B0-7FF57B65A346</gtr:id><gtr:title>Germline JAK2 mutation in a family with hereditary thrombocytosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>545e5ee1ed3230.71828524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>583A25DC-9742-4B9F-8A8F-2CB856A1A6E6</gtr:id><gtr:title>Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f40f4f583726e10dea43821160160bc"><gtr:id>3f40f4f583726e10dea43821160160bc</gtr:id><gtr:otherNames>Kharazi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545e5ee1a48ea5.26243185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A6FCC25-D817-4D3C-A834-595BD8F5BFB3</gtr:id><gtr:title>Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>0A191B11F8E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6308E917-27D9-430E-B37C-2DF8877239F6</gtr:id><gtr:title>Guideline for the diagnosis and management of myelofibrosis.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d26164a28df647b741d87926e375e651"><gtr:id>d26164a28df647b741d87926e375e651</gtr:id><gtr:otherNames>Reilly JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>545e606d3a0287.30679453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>302EF228-B32E-4920-8826-C4122ABE0BAC</gtr:id><gtr:title>Dicer is selectively important for the earliest stages of erythroid development.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/867a455fe097c2dfa583641b7668df6a"><gtr:id>867a455fe097c2dfa583641b7668df6a</gtr:id><gtr:otherNames>Buza-Vidas N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545e5ee245e1d6.03539399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9316623-3AB6-4E65-9443-275801E3F80E</gtr:id><gtr:title>Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85b238b999083dddfa46c534b0bd1c9a"><gtr:id>85b238b999083dddfa46c534b0bd1c9a</gtr:id><gtr:otherNames>Reckzeh K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>545e5fe34228f0.68667504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29558F1F-5F93-4256-AEAD-5835CEAE6FEA</gtr:id><gtr:title>Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38befaa024e88a98a6ac992c4bdb576"><gtr:id>a38befaa024e88a98a6ac992c4bdb576</gtr:id><gtr:otherNames>Harrison CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a93d8c382f632.88130418</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6443</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>